nodes	percent_of_prediction	percent_of_DWPC	metapath
Docetaxel—TUBB2A—hematologic cancer	0.144	0.521	CbGaD
Docetaxel—BCL2—hematologic cancer	0.0788	0.286	CbGaD
Docetaxel—ABCG2—hematologic cancer	0.0377	0.136	CbGaD
Docetaxel—ABCB1—hematologic cancer	0.0157	0.0568	CbGaD
Docetaxel—TUBB8—Vinorelbine—hematologic cancer	0.0129	0.0292	CbGbCtD
Docetaxel—TUBB2A—Vinorelbine—hematologic cancer	0.0129	0.0292	CbGbCtD
Docetaxel—TUBB3—Vinorelbine—hematologic cancer	0.0129	0.0292	CbGbCtD
Docetaxel—TUBB2B—Vinorelbine—hematologic cancer	0.0129	0.0292	CbGbCtD
Docetaxel—TUBB4A—Vinorelbine—hematologic cancer	0.0129	0.0292	CbGbCtD
Docetaxel—TUBB6—Vinorelbine—hematologic cancer	0.0129	0.0292	CbGbCtD
Docetaxel—CYP1B1—Procarbazine—hematologic cancer	0.0121	0.0274	CbGbCtD
Docetaxel—ABCC10—Daunorubicin—hematologic cancer	0.0119	0.027	CbGbCtD
Docetaxel—TUBB1—Vinorelbine—hematologic cancer	0.0108	0.0244	CbGbCtD
Docetaxel—TUBB4B—Vinorelbine—hematologic cancer	0.0108	0.0244	CbGbCtD
Docetaxel—TUBB—Vinorelbine—hematologic cancer	0.0108	0.0244	CbGbCtD
Docetaxel—ABCC10—Cytarabine—hematologic cancer	0.0105	0.0238	CbGbCtD
Docetaxel—TUBB8—Vinblastine—hematologic cancer	0.00794	0.018	CbGbCtD
Docetaxel—TUBB4A—Vinblastine—hematologic cancer	0.00794	0.018	CbGbCtD
Docetaxel—TUBB2B—Vinblastine—hematologic cancer	0.00794	0.018	CbGbCtD
Docetaxel—TUBB3—Vinblastine—hematologic cancer	0.00794	0.018	CbGbCtD
Docetaxel—TUBB2A—Vinblastine—hematologic cancer	0.00794	0.018	CbGbCtD
Docetaxel—TUBB6—Vinblastine—hematologic cancer	0.00794	0.018	CbGbCtD
Docetaxel—TUBB2A—Vincristine—hematologic cancer	0.00781	0.0177	CbGbCtD
Docetaxel—TUBB4A—Vincristine—hematologic cancer	0.00781	0.0177	CbGbCtD
Docetaxel—TUBB6—Vincristine—hematologic cancer	0.00781	0.0177	CbGbCtD
Docetaxel—TUBB8—Vincristine—hematologic cancer	0.00781	0.0177	CbGbCtD
Docetaxel—TUBB2B—Vincristine—hematologic cancer	0.00781	0.0177	CbGbCtD
Docetaxel—TUBB3—Vincristine—hematologic cancer	0.00781	0.0177	CbGbCtD
Docetaxel—TUBB—Vinblastine—hematologic cancer	0.00664	0.015	CbGbCtD
Docetaxel—TUBB4B—Vinblastine—hematologic cancer	0.00664	0.015	CbGbCtD
Docetaxel—TUBB1—Vinblastine—hematologic cancer	0.00664	0.015	CbGbCtD
Docetaxel—TUBB—Vincristine—hematologic cancer	0.00653	0.0148	CbGbCtD
Docetaxel—TUBB4B—Vincristine—hematologic cancer	0.00653	0.0148	CbGbCtD
Docetaxel—TUBB1—Vincristine—hematologic cancer	0.00653	0.0148	CbGbCtD
Docetaxel—ABCC1—Idarubicin—hematologic cancer	0.00651	0.0147	CbGbCtD
Docetaxel—CYP1B1—Daunorubicin—hematologic cancer	0.00649	0.0147	CbGbCtD
Docetaxel—ABCC10—Gemcitabine—hematologic cancer	0.00641	0.0145	CbGbCtD
Docetaxel—ABCG2—Clofarabine—hematologic cancer	0.00526	0.0119	CbGbCtD
Docetaxel—ABCC10—Vincristine—hematologic cancer	0.00499	0.0113	CbGbCtD
Docetaxel—ABCC1—Daunorubicin—hematologic cancer	0.00461	0.0104	CbGbCtD
Docetaxel—ABCC10—Etoposide—hematologic cancer	0.00457	0.0103	CbGbCtD
Docetaxel—CYP1B1—Dasatinib—hematologic cancer	0.00399	0.00903	CbGbCtD
Docetaxel—CYP1B1—Mitoxantrone—hematologic cancer	0.00394	0.00891	CbGbCtD
Docetaxel—ABCC2—Daunorubicin—hematologic cancer	0.00341	0.00771	CbGbCtD
Docetaxel—ABCC10—Doxorubicin—hematologic cancer	0.00312	0.00705	CbGbCtD
Docetaxel—ABCG2—Daunorubicin—hematologic cancer	0.00308	0.00697	CbGbCtD
Docetaxel—ABCC10—Methotrexate—hematologic cancer	0.00302	0.00683	CbGbCtD
Docetaxel—ABCC1—Mitoxantrone—hematologic cancer	0.0028	0.00633	CbGbCtD
Docetaxel—ABCG2—Teniposide—hematologic cancer	0.00268	0.00606	CbGbCtD
Docetaxel—ABCG2—Cladribine—hematologic cancer	0.00257	0.00581	CbGbCtD
Docetaxel—ABCG2—Imatinib—hematologic cancer	0.00236	0.00534	CbGbCtD
Docetaxel—ABCC1—Epirubicin—hematologic cancer	0.00227	0.00513	CbGbCtD
Docetaxel—ABCC1—Irinotecan—hematologic cancer	0.0022	0.00499	CbGbCtD
Docetaxel—ABCG2—Nilotinib—hematologic cancer	0.00215	0.00485	CbGbCtD
Docetaxel—CYP1B1—Dexamethasone—hematologic cancer	0.00204	0.00462	CbGbCtD
Docetaxel—ABCC1—Vinblastine—hematologic cancer	0.00196	0.00443	CbGbCtD
Docetaxel—ABCC1—Vincristine—hematologic cancer	0.00193	0.00436	CbGbCtD
Docetaxel—ABCG2—Dasatinib—hematologic cancer	0.0019	0.00429	CbGbCtD
Docetaxel—ABCB1—Lenalidomide—hematologic cancer	0.0019	0.00429	CbGbCtD
Docetaxel—ABCG2—Mitoxantrone—hematologic cancer	0.00187	0.00424	CbGbCtD
Docetaxel—CYP3A7—Ifosfamide—hematologic cancer	0.00183	0.00413	CbGbCtD
Docetaxel—CYP3A7-CYP3A51P—Ifosfamide—hematologic cancer	0.00183	0.00413	CbGbCtD
Docetaxel—ABCC1—Etoposide—hematologic cancer	0.00177	0.00399	CbGbCtD
Docetaxel—CYP3A7-CYP3A51P—Imatinib—hematologic cancer	0.00174	0.00395	CbGbCtD
Docetaxel—CYP3A7—Imatinib—hematologic cancer	0.00174	0.00395	CbGbCtD
Docetaxel—CYP3A5—Daunorubicin—hematologic cancer	0.00171	0.00386	CbGbCtD
Docetaxel—CYP1B1—Doxorubicin—hematologic cancer	0.0017	0.00383	CbGbCtD
Docetaxel—SLCO1B3—Methotrexate—hematologic cancer	0.00169	0.00382	CbGbCtD
Docetaxel—ABCC2—Irinotecan—hematologic cancer	0.00163	0.00369	CbGbCtD
Docetaxel—CYP3A5—Thalidomide—hematologic cancer	0.00156	0.00352	CbGbCtD
Docetaxel—SLC22A7—Methotrexate—hematologic cancer	0.00149	0.00336	CbGbCtD
Docetaxel—CYP3A5—Teniposide—hematologic cancer	0.00148	0.00336	CbGbCtD
Docetaxel—ABCG2—Irinotecan—hematologic cancer	0.00148	0.00334	CbGbCtD
Docetaxel—ABCC2—Vinblastine—hematologic cancer	0.00145	0.00328	CbGbCtD
Docetaxel—ABCC2—Vincristine—hematologic cancer	0.00143	0.00323	CbGbCtD
Docetaxel—CYP3A5—Ifosfamide—hematologic cancer	0.00137	0.0031	CbGbCtD
Docetaxel—ABCC2—Cisplatin—hematologic cancer	0.00133	0.00301	CbGbCtD
Docetaxel—CYP3A5—Imatinib—hematologic cancer	0.00131	0.00296	CbGbCtD
Docetaxel—ABCC2—Etoposide—hematologic cancer	0.00131	0.00296	CbGbCtD
Docetaxel—ABCG2—Vincristine—hematologic cancer	0.00129	0.00292	CbGbCtD
Docetaxel—KIF11—blood—hematologic cancer	0.00122	0.0308	CbGeAlD
Docetaxel—ABCC1—Doxorubicin—hematologic cancer	0.0012	0.00272	CbGbCtD
Docetaxel—ABCG2—Cisplatin—hematologic cancer	0.0012	0.00272	CbGbCtD
Docetaxel—ABCG2—Etoposide—hematologic cancer	0.00118	0.00267	CbGbCtD
Docetaxel—KIF11—bone marrow—hematologic cancer	0.00118	0.0298	CbGeAlD
Docetaxel—ABCC1—Methotrexate—hematologic cancer	0.00117	0.00264	CbGbCtD
Docetaxel—CYP3A4—Bexarotene—hematologic cancer	0.00114	0.00257	CbGbCtD
Docetaxel—ABCB1—Daunorubicin—hematologic cancer	0.00111	0.00251	CbGbCtD
Docetaxel—CYP3A7-CYP3A51P—Irinotecan—hematologic cancer	0.00109	0.00246	CbGbCtD
Docetaxel—CYP3A7—Irinotecan—hematologic cancer	0.00109	0.00246	CbGbCtD
Docetaxel—ABCB1—Alitretinoin—hematologic cancer	0.00109	0.00246	CbGbCtD
Docetaxel—ABCC2—Dexamethasone—hematologic cancer	0.00107	0.00243	CbGbCtD
Docetaxel—KIF11—lung—hematologic cancer	0.00107	0.027	CbGeAlD
Docetaxel—CYP3A4—Lomustine—hematologic cancer	0.00106	0.00239	CbGbCtD
Docetaxel—CYP3A4—Busulfan—hematologic cancer	0.00106	0.00239	CbGbCtD
Docetaxel—CYP3A5—Dasatinib—hematologic cancer	0.00105	0.00238	CbGbCtD
Docetaxel—KIF11—testis—hematologic cancer	0.00101	0.0255	CbGeAlD
Docetaxel—ABCG2—Dexamethasone—hematologic cancer	0.000971	0.0022	CbGbCtD
Docetaxel—CYP3A7—Vincristine—hematologic cancer	0.000952	0.00215	CbGbCtD
Docetaxel—CYP3A7-CYP3A51P—Vincristine—hematologic cancer	0.000952	0.00215	CbGbCtD
Docetaxel—CYP3A4—Thiotepa—hematologic cancer	0.000942	0.00213	CbGbCtD
Docetaxel—ABCC2—Doxorubicin—hematologic cancer	0.000891	0.00202	CbGbCtD
Docetaxel—Cabazitaxel—TUBB2A—hematologic cancer	0.000886	0.342	CrCbGaD
Docetaxel—ABCC2—Methotrexate—hematologic cancer	0.000864	0.00195	CbGbCtD
Docetaxel—ABCB1—Imatinib—hematologic cancer	0.000852	0.00193	CbGbCtD
Docetaxel—MAP4—hematopoietic system—hematologic cancer	0.000846	0.0214	CbGeAlD
Docetaxel—TUBB3—hematopoietic system—hematologic cancer	0.000846	0.0214	CbGeAlD
Docetaxel—TUBB1—hematopoietic system—hematologic cancer	0.000827	0.0209	CbGeAlD
Docetaxel—CYP3A5—Irinotecan—hematologic cancer	0.000817	0.00185	CbGbCtD
Docetaxel—ABCG2—Doxorubicin—hematologic cancer	0.000806	0.00182	CbGbCtD
Docetaxel—ABCG2—Methotrexate—hematologic cancer	0.000781	0.00177	CbGbCtD
Docetaxel—ABCB1—Nilotinib—hematologic cancer	0.000774	0.00175	CbGbCtD
Docetaxel—BCL2—hematopoietic system—hematologic cancer	0.000769	0.0195	CbGeAlD
Docetaxel—ABCB1—Vinorelbine—hematologic cancer	0.000767	0.00174	CbGbCtD
Docetaxel—CYP3A4—Methoxsalen—hematologic cancer	0.000732	0.00166	CbGbCtD
Docetaxel—KIF11—lymph node—hematologic cancer	0.000729	0.0185	CbGeAlD
Docetaxel—CYP3A7—Dexamethasone—hematologic cancer	0.000718	0.00162	CbGbCtD
Docetaxel—CYP3A7-CYP3A51P—Dexamethasone—hematologic cancer	0.000718	0.00162	CbGbCtD
Docetaxel—Paclitaxel—TUBB2A—hematologic cancer	0.000715	0.277	CrCbGaD
Docetaxel—CYP3A5—Vincristine—hematologic cancer	0.000714	0.00162	CbGbCtD
Docetaxel—CYP3A4—Bortezomib—hematologic cancer	0.000696	0.00158	CbGbCtD
Docetaxel—ABCB1—Dasatinib—hematologic cancer	0.000684	0.00155	CbGbCtD
Docetaxel—TUBB8—testis—hematologic cancer	0.00068	0.0172	CbGeAlD
Docetaxel—ABCB1—Mitoxantrone—hematologic cancer	0.000676	0.00153	CbGbCtD
Docetaxel—MAP2—hematopoietic system—hematologic cancer	0.000666	0.0169	CbGeAlD
Docetaxel—CYP3A4—Daunorubicin—hematologic cancer	0.000666	0.00151	CbGbCtD
Docetaxel—CYP3A5—Etoposide—hematologic cancer	0.000655	0.00148	CbGbCtD
Docetaxel—MAP4—gonad—hematologic cancer	0.000643	0.0163	CbGeAlD
Docetaxel—ABCB1—Betamethasone—hematologic cancer	0.000602	0.00136	CbGbCtD
Docetaxel—ABCB1—Gemcitabine—hematologic cancer	0.000597	0.00135	CbGbCtD
Docetaxel—ABCB1—Prednisolone—hematologic cancer	0.000594	0.00134	CbGbCtD
Docetaxel—MAPT—testis—hematologic cancer	0.00059	0.0149	CbGeAlD
Docetaxel—CYP3A4—Cytarabine—hematologic cancer	0.000588	0.00133	CbGbCtD
Docetaxel—BCL2—gonad—hematologic cancer	0.000585	0.0148	CbGeAlD
Docetaxel—CYP3A4—Teniposide—hematologic cancer	0.000579	0.00131	CbGbCtD
Docetaxel—ABCB1—Prednisone—hematologic cancer	0.000561	0.00127	CbGbCtD
Docetaxel—MAP4—blood—hematologic cancer	0.000561	0.0142	CbGeAlD
Docetaxel—TUBB3—blood—hematologic cancer	0.000561	0.0142	CbGeAlD
Docetaxel—TUBB1—blood—hematologic cancer	0.000548	0.0139	CbGeAlD
Docetaxel—CYP3A5—Dexamethasone—hematologic cancer	0.000538	0.00122	CbGbCtD
Docetaxel—CYP3A4—Ifosfamide—hematologic cancer	0.000534	0.00121	CbGbCtD
Docetaxel—ABCB1—Irinotecan—hematologic cancer	0.000532	0.0012	CbGbCtD
Docetaxel—TUBB1—bone marrow—hematologic cancer	0.00053	0.0134	CbGeAlD
Docetaxel—TUBB4A—hematopoietic system—hematologic cancer	0.000515	0.013	CbGeAlD
Docetaxel—CYP3A4—Imatinib—hematologic cancer	0.00051	0.00115	CbGbCtD
Docetaxel—BCL2—blood—hematologic cancer	0.00051	0.0129	CbGeAlD
Docetaxel—MAP2—gonad—hematologic cancer	0.000507	0.0128	CbGeAlD
Docetaxel—BCL2—bone marrow—hematologic cancer	0.000493	0.0125	CbGeAlD
Docetaxel—TUBB3—lung—hematologic cancer	0.000491	0.0124	CbGeAlD
Docetaxel—MAP4—lung—hematologic cancer	0.000491	0.0124	CbGeAlD
Docetaxel—CYP3A4—Ruxolitinib—hematologic cancer	0.00048	0.00109	CbGbCtD
Docetaxel—ABCB1—Vinblastine—hematologic cancer	0.000473	0.00107	CbGbCtD
Docetaxel—TUBB2A—hematopoietic system—hematologic cancer	0.000469	0.0119	CbGeAlD
Docetaxel—ABCB1—Vincristine—hematologic cancer	0.000465	0.00105	CbGbCtD
Docetaxel—TUBB3—testis—hematologic cancer	0.000464	0.0117	CbGeAlD
Docetaxel—MAP4—testis—hematologic cancer	0.000464	0.0117	CbGeAlD
Docetaxel—CYP3A4—Nilotinib—hematologic cancer	0.000464	0.00105	CbGbCtD
Docetaxel—TUBB6—hematopoietic system—hematologic cancer	0.000462	0.0117	CbGeAlD
Docetaxel—CYP3A4—Vinorelbine—hematologic cancer	0.00046	0.00104	CbGbCtD
Docetaxel—TUBB1—testis—hematologic cancer	0.000453	0.0115	CbGeAlD
Docetaxel—BCL2—lung—hematologic cancer	0.000447	0.0113	CbGeAlD
Docetaxel—MAP2—blood—hematologic cancer	0.000441	0.0112	CbGeAlD
Docetaxel—EGFR—lung—hematologic cancer	0.000441	0.0112	CbGeAlD
Docetaxel—ABCB1—Cisplatin—hematologic cancer	0.000434	0.000981	CbGbCtD
Docetaxel—SLCO1B3—lung—hematologic cancer	0.00043	0.0109	CbGeAlD
Docetaxel—MAPT—lymph node—hematologic cancer	0.000428	0.0108	CbGeAlD
Docetaxel—ABCB1—Etoposide—hematologic cancer	0.000426	0.000964	CbGbCtD
Docetaxel—BCL2—testis—hematologic cancer	0.000422	0.0107	CbGeAlD
Docetaxel—CYP3A4—Triamcinolone—hematologic cancer	0.000421	0.000951	CbGbCtD
Docetaxel—EGFR—testis—hematologic cancer	0.000417	0.0105	CbGeAlD
Docetaxel—CYP3A4—Dasatinib—hematologic cancer	0.00041	0.000927	CbGbCtD
Docetaxel—CYP3A4—Mitoxantrone—hematologic cancer	0.000405	0.000916	CbGbCtD
Docetaxel—ABCC10—hematopoietic system—hematologic cancer	0.000405	0.0102	CbGeAlD
Docetaxel—TUBB4B—hematopoietic system—hematologic cancer	0.000402	0.0102	CbGeAlD
Docetaxel—Paclitaxel—BCL2—hematologic cancer	0.000392	0.151	CrCbGaD
Docetaxel—TUBB4A—gonad—hematologic cancer	0.000392	0.00991	CbGeAlD
Docetaxel—MAP2—lung—hematologic cancer	0.000387	0.00979	CbGeAlD
Docetaxel—TUBB2B—gonad—hematologic cancer	0.000378	0.00958	CbGeAlD
Docetaxel—MAP2—testis—hematologic cancer	0.000365	0.00924	CbGeAlD
Docetaxel—CYP3A4—Betamethasone—hematologic cancer	0.000361	0.000816	CbGbCtD
Docetaxel—CYP3A4—Prednisolone—hematologic cancer	0.000356	0.000805	CbGbCtD
Docetaxel—TUBB6—gonad—hematologic cancer	0.000351	0.00889	CbGeAlD
Docetaxel—ABCB1—Dexamethasone—hematologic cancer	0.00035	0.000792	CbGbCtD
Docetaxel—TUBB4A—blood—hematologic cancer	0.000341	0.00863	CbGeAlD
Docetaxel—CYP3A4—Prednisone—hematologic cancer	0.000336	0.00076	CbGbCtD
Docetaxel—MAP4—lymph node—hematologic cancer	0.000336	0.00851	CbGeAlD
Docetaxel—CYP3A4—Irinotecan—hematologic cancer	0.000319	0.000721	CbGbCtD
Docetaxel—CYP1B1—hematopoietic system—hematologic cancer	0.000318	0.00805	CbGeAlD
Docetaxel—SLC22A7—testis—hematologic cancer	0.000316	0.00799	CbGeAlD
Docetaxel—TUBB—blood—hematologic cancer	0.000312	0.0079	CbGeAlD
Docetaxel—TUBB2A—blood—hematologic cancer	0.00031	0.00785	CbGeAlD
Docetaxel—ABCC10—gonad—hematologic cancer	0.000308	0.00778	CbGeAlD
Docetaxel—TUBB6—blood—hematologic cancer	0.000306	0.00775	CbGeAlD
Docetaxel—BCL2—lymph node—hematologic cancer	0.000306	0.00773	CbGeAlD
Docetaxel—TUBB4B—gonad—hematologic cancer	0.000305	0.00773	CbGeAlD
Docetaxel—EGFR—lymph node—hematologic cancer	0.000302	0.00764	CbGeAlD
Docetaxel—TUBB—bone marrow—hematologic cancer	0.000302	0.00764	CbGeAlD
Docetaxel—TUBB2A—bone marrow—hematologic cancer	0.0003	0.0076	CbGeAlD
Docetaxel—TUBB4A—lung—hematologic cancer	0.000299	0.00757	CbGeAlD
Docetaxel—TUBB6—bone marrow—hematologic cancer	0.000296	0.0075	CbGeAlD
Docetaxel—ABCB1—Doxorubicin—hematologic cancer	0.000291	0.000657	CbGbCtD
Docetaxel—TUBB2B—lung—hematologic cancer	0.000289	0.00731	CbGeAlD
Docetaxel—CYP3A4—Vinblastine—hematologic cancer	0.000283	0.000641	CbGbCtD
Docetaxel—TUBB4A—testis—hematologic cancer	0.000282	0.00714	CbGeAlD
Docetaxel—ABCB1—Methotrexate—hematologic cancer	0.000282	0.000637	CbGbCtD
Docetaxel—CYP3A4—Vincristine—hematologic cancer	0.000279	0.00063	CbGbCtD
Docetaxel—TUBB—lung—hematologic cancer	0.000274	0.00692	CbGeAlD
Docetaxel—TUBB2B—testis—hematologic cancer	0.000273	0.0069	CbGeAlD
Docetaxel—TUBB2A—lung—hematologic cancer	0.000272	0.00688	CbGeAlD
Docetaxel—TUBB6—lung—hematologic cancer	0.000268	0.00679	CbGeAlD
Docetaxel—ABCC10—blood—hematologic cancer	0.000268	0.00678	CbGeAlD
Docetaxel—TUBB4B—blood—hematologic cancer	0.000266	0.00673	CbGeAlD
Docetaxel—MAP2—lymph node—hematologic cancer	0.000265	0.0067	CbGeAlD
Docetaxel—ABCC10—bone marrow—hematologic cancer	0.000259	0.00656	CbGeAlD
Docetaxel—TUBB—testis—hematologic cancer	0.000258	0.00653	CbGeAlD
Docetaxel—TUBB4B—bone marrow—hematologic cancer	0.000258	0.00652	CbGeAlD
Docetaxel—TUBB2A—testis—hematologic cancer	0.000257	0.0065	CbGeAlD
Docetaxel—CYP3A4—Etoposide—hematologic cancer	0.000255	0.000577	CbGbCtD
Docetaxel—TUBB6—testis—hematologic cancer	0.000253	0.00641	CbGeAlD
Docetaxel—KIF11—Topotecan—Irinotecan—hematologic cancer	0.000242	0.112	CbGdCrCtD
Docetaxel—CYP1B1—gonad—hematologic cancer	0.000242	0.00612	CbGeAlD
Docetaxel—ABCC10—lung—hematologic cancer	0.000235	0.00595	CbGeAlD
Docetaxel—TUBB4B—lung—hematologic cancer	0.000233	0.0059	CbGeAlD
Docetaxel—Cabazitaxel—ABCG2—hematologic cancer	0.000232	0.0896	CrCbGaD
Docetaxel—ABCC10—testis—hematologic cancer	0.000222	0.00561	CbGeAlD
Docetaxel—TUBB4B—testis—hematologic cancer	0.00022	0.00557	CbGeAlD
Docetaxel—CYP3A5—hematopoietic system—hematologic cancer	0.00022	0.00556	CbGeAlD
Docetaxel—ABCC2—blood—hematologic cancer	0.000215	0.00545	CbGeAlD
Docetaxel—CYP1B1—blood—hematologic cancer	0.000211	0.00533	CbGeAlD
Docetaxel—CYP3A4—Dexamethasone—hematologic cancer	0.00021	0.000475	CbGbCtD
Docetaxel—TUBB4A—lymph node—hematologic cancer	0.000205	0.00518	CbGeAlD
Docetaxel—TUBB2B—lymph node—hematologic cancer	0.000198	0.005	CbGeAlD
Docetaxel—ABCC1—blood—hematologic cancer	0.00019	0.0048	CbGeAlD
Docetaxel—Paclitaxel—ABCG2—hematologic cancer	0.000187	0.0724	CrCbGaD
Docetaxel—TUBB—lymph node—hematologic cancer	0.000187	0.00473	CbGeAlD
Docetaxel—TUBB2A—lymph node—hematologic cancer	0.000186	0.00471	CbGeAlD
Docetaxel—CYP1B1—lung—hematologic cancer	0.000185	0.00468	CbGeAlD
Docetaxel—TUBB6—lymph node—hematologic cancer	0.000184	0.00464	CbGeAlD
Docetaxel—ABCC2—testis—hematologic cancer	0.000178	0.0045	CbGeAlD
Docetaxel—CYP1B1—testis—hematologic cancer	0.000174	0.00441	CbGeAlD
Docetaxel—CYP3A4—Doxorubicin—hematologic cancer	0.000174	0.000394	CbGbCtD
Docetaxel—ABCC1—lung—hematologic cancer	0.000166	0.00421	CbGeAlD
Docetaxel—CYP3A4—hematopoietic system—hematologic cancer	0.000165	0.00418	CbGeAlD
Docetaxel—ABCC10—lymph node—hematologic cancer	0.000161	0.00407	CbGeAlD
Docetaxel—TUBB4B—lymph node—hematologic cancer	0.00016	0.00404	CbGeAlD
Docetaxel—ABCG2—blood—hematologic cancer	0.000157	0.00397	CbGeAlD
Docetaxel—ABCC1—testis—hematologic cancer	0.000157	0.00397	CbGeAlD
Docetaxel—ABCG2—bone marrow—hematologic cancer	0.000152	0.00384	CbGeAlD
Docetaxel—CYP3A5—blood—hematologic cancer	0.000146	0.00369	CbGeAlD
Docetaxel—ABCG2—lung—hematologic cancer	0.000138	0.00348	CbGeAlD
Docetaxel—BCL2—Isotretinoin—Alitretinoin—hematologic cancer	0.000133	0.0615	CbGdCrCtD
Docetaxel—BCL2—Tretinoin—Alitretinoin—hematologic cancer	0.000133	0.0615	CbGdCrCtD
Docetaxel—ABCG2—testis—hematologic cancer	0.00013	0.00328	CbGeAlD
Docetaxel—ABCC2—lymph node—hematologic cancer	0.000129	0.00327	CbGeAlD
Docetaxel—CYP3A5—lung—hematologic cancer	0.000128	0.00323	CbGeAlD
Docetaxel—CYP1B1—lymph node—hematologic cancer	0.000126	0.0032	CbGeAlD
Docetaxel—ABCB1—hematopoietic system—hematologic cancer	0.000117	0.00296	CbGeAlD
Docetaxel—ABCC1—lymph node—hematologic cancer	0.000114	0.00288	CbGeAlD
Docetaxel—CYP3A4—blood—hematologic cancer	0.000109	0.00277	CbGeAlD
Docetaxel—KIF11—Teniposide—Etoposide—hematologic cancer	0.000109	0.0504	CbGdCrCtD
Docetaxel—KIF11—Clofarabine—Nelarabine—hematologic cancer	9.79e-05	0.0452	CbGdCrCtD
Docetaxel—Cabazitaxel—ABCB1—hematologic cancer	9.65e-05	0.0373	CrCbGaD
Docetaxel—ABCG2—lymph node—hematologic cancer	9.41e-05	0.00238	CbGeAlD
Docetaxel—KIF11—Vinblastine—Vinorelbine—hematologic cancer	9.4e-05	0.0434	CbGdCrCtD
Docetaxel—ABCB1—gonad—hematologic cancer	8.88e-05	0.00225	CbGeAlD
Docetaxel—KIF11—Cytarabine—Clofarabine—hematologic cancer	8.86e-05	0.0409	CbGdCrCtD
Docetaxel—TUBB—Menadione—Thalidomide—hematologic cancer	8.82e-05	0.0407	CbGdCrCtD
Docetaxel—KIF11—Cytarabine—Nelarabine—hematologic cancer	8.33e-05	0.0385	CbGdCrCtD
Docetaxel—Paclitaxel—ABCB1—hematologic cancer	7.8e-05	0.0301	CrCbGaD
Docetaxel—ABCB1—blood—hematologic cancer	7.74e-05	0.00196	CbGeAlD
Docetaxel—KIF11—Clofarabine—Fludarabine—hematologic cancer	7.64e-05	0.0353	CbGdCrCtD
Docetaxel—KIF11—Vinblastine—Vincristine—hematologic cancer	7.52e-05	0.0347	CbGdCrCtD
Docetaxel—ABCB1—bone marrow—hematologic cancer	7.49e-05	0.00189	CbGeAlD
Docetaxel—KIF11—Clofarabine—Cytarabine—hematologic cancer	7.22e-05	0.0333	CbGdCrCtD
Docetaxel—KIF11—Clofarabine—Cladribine—hematologic cancer	7.04e-05	0.0325	CbGdCrCtD
Docetaxel—TUBB6—Vitamin A—Alitretinoin—hematologic cancer	6.9e-05	0.0319	CbGdCrCtD
Docetaxel—ABCB1—lung—hematologic cancer	6.78e-05	0.00172	CbGeAlD
Docetaxel—KIF11—Gemcitabine—Cytarabine—hematologic cancer	6.69e-05	0.0309	CbGdCrCtD
Docetaxel—KIF11—Cytarabine—Fludarabine—hematologic cancer	6.5e-05	0.03	CbGdCrCtD
Docetaxel—ABCB1—testis—hematologic cancer	6.4e-05	0.00162	CbGeAlD
Docetaxel—KIF11—Cytarabine—Gemcitabine—hematologic cancer	6.14e-05	0.0284	CbGdCrCtD
Docetaxel—TUBB6—Zalcitabine—Gemcitabine—hematologic cancer	5.48e-05	0.0253	CbGdCrCtD
Docetaxel—TUBB6—Zalcitabine—Cytarabine—hematologic cancer	5.48e-05	0.0253	CbGdCrCtD
Docetaxel—TUBB6—Isotretinoin—Alitretinoin—hematologic cancer	4.82e-05	0.0223	CbGdCrCtD
Docetaxel—TUBB6—Tretinoin—Alitretinoin—hematologic cancer	4.82e-05	0.0223	CbGdCrCtD
Docetaxel—ABCB1—lymph node—hematologic cancer	4.64e-05	0.00117	CbGeAlD
Docetaxel—TUBB—Azacitidine—Pentostatin—hematologic cancer	4.52e-05	0.0209	CbGdCrCtD
Docetaxel—TUBB—Azacitidine—Clofarabine—hematologic cancer	4.03e-05	0.0186	CbGdCrCtD
Docetaxel—TUBB—Azacitidine—Nelarabine—hematologic cancer	3.79e-05	0.0175	CbGdCrCtD
Docetaxel—TUBB—Azacitidine—Fludarabine—hematologic cancer	2.96e-05	0.0136	CbGdCrCtD
Docetaxel—TUBB—Azacitidine—Cytarabine—hematologic cancer	2.79e-05	0.0129	CbGdCrCtD
Docetaxel—TUBB—Azacitidine—Gemcitabine—hematologic cancer	2.79e-05	0.0129	CbGdCrCtD
Docetaxel—TUBB—Azacitidine—Cladribine—hematologic cancer	2.72e-05	0.0126	CbGdCrCtD
Docetaxel—TUBB6—Azacitidine—Pentostatin—hematologic cancer	1.87e-05	0.00862	CbGdCrCtD
Docetaxel—TUBB6—Azacitidine—Clofarabine—hematologic cancer	1.66e-05	0.00768	CbGdCrCtD
Docetaxel—TUBB6—Azacitidine—Nelarabine—hematologic cancer	1.56e-05	0.00722	CbGdCrCtD
Docetaxel—TUBB6—Azacitidine—Fludarabine—hematologic cancer	1.22e-05	0.00564	CbGdCrCtD
Docetaxel—TUBB6—Azacitidine—Gemcitabine—hematologic cancer	1.15e-05	0.00532	CbGdCrCtD
Docetaxel—TUBB6—Azacitidine—Cytarabine—hematologic cancer	1.15e-05	0.00532	CbGdCrCtD
Docetaxel—TUBB6—Azacitidine—Cladribine—hematologic cancer	1.12e-05	0.00519	CbGdCrCtD
Docetaxel—Gastrointestinal disorder—Dexamethasone—hematologic cancer	5.98e-06	4.12e-05	CcSEcCtD
Docetaxel—Gastrointestinal disorder—Betamethasone—hematologic cancer	5.98e-06	4.12e-05	CcSEcCtD
Docetaxel—Back pain—Methotrexate—hematologic cancer	5.97e-06	4.12e-05	CcSEcCtD
Docetaxel—Fatigue—Betamethasone—hematologic cancer	5.97e-06	4.11e-05	CcSEcCtD
Docetaxel—Fatigue—Dexamethasone—hematologic cancer	5.97e-06	4.11e-05	CcSEcCtD
Docetaxel—Chills—Epirubicin—hematologic cancer	5.96e-06	4.1e-05	CcSEcCtD
Docetaxel—Pruritus—Etoposide—hematologic cancer	5.95e-06	4.1e-05	CcSEcCtD
Docetaxel—Shock—Prednisone—hematologic cancer	5.93e-06	4.09e-05	CcSEcCtD
Docetaxel—Arrhythmia—Epirubicin—hematologic cancer	5.93e-06	4.09e-05	CcSEcCtD
Docetaxel—Pain—Betamethasone—hematologic cancer	5.92e-06	4.08e-05	CcSEcCtD
Docetaxel—Pain—Dexamethasone—hematologic cancer	5.92e-06	4.08e-05	CcSEcCtD
Docetaxel—Visual impairment—Doxorubicin—hematologic cancer	5.92e-06	4.08e-05	CcSEcCtD
Docetaxel—Nervous system disorder—Prednisone—hematologic cancer	5.92e-06	4.08e-05	CcSEcCtD
Docetaxel—Tachycardia—Prednisone—hematologic cancer	5.89e-06	4.06e-05	CcSEcCtD
Docetaxel—Alopecia—Epirubicin—hematologic cancer	5.87e-06	4.04e-05	CcSEcCtD
Docetaxel—Skin disorder—Prednisone—hematologic cancer	5.86e-06	4.04e-05	CcSEcCtD
Docetaxel—Nausea—Gemcitabine—hematologic cancer	5.85e-06	4.03e-05	CcSEcCtD
Docetaxel—Vomiting—Cisplatin—hematologic cancer	5.84e-06	4.02e-05	CcSEcCtD
Docetaxel—Mental disorder—Epirubicin—hematologic cancer	5.82e-06	4.01e-05	CcSEcCtD
Docetaxel—Erythema multiforme—Doxorubicin—hematologic cancer	5.81e-06	4e-05	CcSEcCtD
Docetaxel—Rash—Cisplatin—hematologic cancer	5.79e-06	3.99e-05	CcSEcCtD
Docetaxel—Dermatitis—Cisplatin—hematologic cancer	5.79e-06	3.99e-05	CcSEcCtD
Docetaxel—Malnutrition—Epirubicin—hematologic cancer	5.78e-06	3.98e-05	CcSEcCtD
Docetaxel—Erythema—Epirubicin—hematologic cancer	5.78e-06	3.98e-05	CcSEcCtD
Docetaxel—Diarrhoea—Etoposide—hematologic cancer	5.76e-06	3.97e-05	CcSEcCtD
Docetaxel—Anorexia—Prednisone—hematologic cancer	5.75e-06	3.96e-05	CcSEcCtD
Docetaxel—Eye disorder—Doxorubicin—hematologic cancer	5.74e-06	3.96e-05	CcSEcCtD
Docetaxel—Anaemia—Methotrexate—hematologic cancer	5.71e-06	3.93e-05	CcSEcCtD
Docetaxel—Feeling abnormal—Betamethasone—hematologic cancer	5.71e-06	3.93e-05	CcSEcCtD
Docetaxel—Feeling abnormal—Dexamethasone—hematologic cancer	5.71e-06	3.93e-05	CcSEcCtD
Docetaxel—Flushing—Doxorubicin—hematologic cancer	5.7e-06	3.93e-05	CcSEcCtD
Docetaxel—Cardiac disorder—Doxorubicin—hematologic cancer	5.7e-06	3.93e-05	CcSEcCtD
Docetaxel—Gastrointestinal pain—Betamethasone—hematologic cancer	5.66e-06	3.9e-05	CcSEcCtD
Docetaxel—Gastrointestinal pain—Dexamethasone—hematologic cancer	5.66e-06	3.9e-05	CcSEcCtD
Docetaxel—Dysgeusia—Epirubicin—hematologic cancer	5.66e-06	3.9e-05	CcSEcCtD
Docetaxel—Hypersensitivity—Triamcinolone—hematologic cancer	5.62e-06	3.87e-05	CcSEcCtD
Docetaxel—Back pain—Epirubicin—hematologic cancer	5.59e-06	3.85e-05	CcSEcCtD
Docetaxel—Angiopathy—Doxorubicin—hematologic cancer	5.57e-06	3.84e-05	CcSEcCtD
Docetaxel—Dizziness—Etoposide—hematologic cancer	5.57e-06	3.83e-05	CcSEcCtD
Docetaxel—Muscle spasms—Epirubicin—hematologic cancer	5.56e-06	3.83e-05	CcSEcCtD
Docetaxel—Immune system disorder—Doxorubicin—hematologic cancer	5.55e-06	3.82e-05	CcSEcCtD
Docetaxel—Mediastinal disorder—Doxorubicin—hematologic cancer	5.54e-06	3.81e-05	CcSEcCtD
Docetaxel—Leukopenia—Methotrexate—hematologic cancer	5.53e-06	3.81e-05	CcSEcCtD
Docetaxel—Chills—Doxorubicin—hematologic cancer	5.51e-06	3.8e-05	CcSEcCtD
Docetaxel—Musculoskeletal discomfort—Prednisone—hematologic cancer	5.5e-06	3.79e-05	CcSEcCtD
Docetaxel—Dizziness—Prednisolone—hematologic cancer	5.49e-06	3.78e-05	CcSEcCtD
Docetaxel—Arrhythmia—Doxorubicin—hematologic cancer	5.49e-06	3.78e-05	CcSEcCtD
Docetaxel—Asthenia—Triamcinolone—hematologic cancer	5.48e-06	3.77e-05	CcSEcCtD
Docetaxel—Abdominal pain—Dexamethasone—hematologic cancer	5.48e-06	3.77e-05	CcSEcCtD
Docetaxel—Body temperature increased—Dexamethasone—hematologic cancer	5.48e-06	3.77e-05	CcSEcCtD
Docetaxel—Body temperature increased—Betamethasone—hematologic cancer	5.48e-06	3.77e-05	CcSEcCtD
Docetaxel—Abdominal pain—Betamethasone—hematologic cancer	5.48e-06	3.77e-05	CcSEcCtD
Docetaxel—Nausea—Cisplatin—hematologic cancer	5.46e-06	3.76e-05	CcSEcCtD
Docetaxel—Insomnia—Prednisone—hematologic cancer	5.46e-06	3.76e-05	CcSEcCtD
Docetaxel—Alopecia—Doxorubicin—hematologic cancer	5.43e-06	3.74e-05	CcSEcCtD
Docetaxel—Paraesthesia—Prednisone—hematologic cancer	5.42e-06	3.73e-05	CcSEcCtD
Docetaxel—Pruritus—Triamcinolone—hematologic cancer	5.4e-06	3.72e-05	CcSEcCtD
Docetaxel—Cough—Methotrexate—hematologic cancer	5.39e-06	3.71e-05	CcSEcCtD
Docetaxel—Mental disorder—Doxorubicin—hematologic cancer	5.38e-06	3.71e-05	CcSEcCtD
Docetaxel—Convulsion—Methotrexate—hematologic cancer	5.35e-06	3.69e-05	CcSEcCtD
Docetaxel—Vomiting—Etoposide—hematologic cancer	5.35e-06	3.69e-05	CcSEcCtD
Docetaxel—Malnutrition—Doxorubicin—hematologic cancer	5.35e-06	3.68e-05	CcSEcCtD
Docetaxel—Erythema—Doxorubicin—hematologic cancer	5.35e-06	3.68e-05	CcSEcCtD
Docetaxel—Anaemia—Epirubicin—hematologic cancer	5.34e-06	3.68e-05	CcSEcCtD
Docetaxel—Dyspepsia—Prednisone—hematologic cancer	5.31e-06	3.66e-05	CcSEcCtD
Docetaxel—Rash—Etoposide—hematologic cancer	5.31e-06	3.66e-05	CcSEcCtD
Docetaxel—Dermatitis—Etoposide—hematologic cancer	5.3e-06	3.65e-05	CcSEcCtD
Docetaxel—Headache—Etoposide—hematologic cancer	5.27e-06	3.63e-05	CcSEcCtD
Docetaxel—Chest pain—Methotrexate—hematologic cancer	5.26e-06	3.62e-05	CcSEcCtD
Docetaxel—Arthralgia—Methotrexate—hematologic cancer	5.26e-06	3.62e-05	CcSEcCtD
Docetaxel—Myalgia—Methotrexate—hematologic cancer	5.26e-06	3.62e-05	CcSEcCtD
Docetaxel—Decreased appetite—Prednisone—hematologic cancer	5.24e-06	3.61e-05	CcSEcCtD
Docetaxel—Dysgeusia—Doxorubicin—hematologic cancer	5.24e-06	3.61e-05	CcSEcCtD
Docetaxel—Rash—Prednisolone—hematologic cancer	5.23e-06	3.61e-05	CcSEcCtD
Docetaxel—Dermatitis—Prednisolone—hematologic cancer	5.23e-06	3.6e-05	CcSEcCtD
Docetaxel—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	5.22e-06	3.6e-05	CcSEcCtD
Docetaxel—Fatigue—Prednisone—hematologic cancer	5.2e-06	3.58e-05	CcSEcCtD
Docetaxel—Headache—Prednisolone—hematologic cancer	5.2e-06	3.58e-05	CcSEcCtD
Docetaxel—Syncope—Epirubicin—hematologic cancer	5.18e-06	3.57e-05	CcSEcCtD
Docetaxel—Leukopenia—Epirubicin—hematologic cancer	5.17e-06	3.56e-05	CcSEcCtD
Docetaxel—Back pain—Doxorubicin—hematologic cancer	5.17e-06	3.56e-05	CcSEcCtD
Docetaxel—Constipation—Prednisone—hematologic cancer	5.16e-06	3.55e-05	CcSEcCtD
Docetaxel—Muscle spasms—Doxorubicin—hematologic cancer	5.14e-06	3.54e-05	CcSEcCtD
Docetaxel—Palpitations—Epirubicin—hematologic cancer	5.11e-06	3.52e-05	CcSEcCtD
Docetaxel—Confusional state—Methotrexate—hematologic cancer	5.08e-06	3.5e-05	CcSEcCtD
Docetaxel—Loss of consciousness—Epirubicin—hematologic cancer	5.08e-06	3.5e-05	CcSEcCtD
Docetaxel—Dizziness—Triamcinolone—hematologic cancer	5.05e-06	3.48e-05	CcSEcCtD
Docetaxel—Cough—Epirubicin—hematologic cancer	5.04e-06	3.48e-05	CcSEcCtD
Docetaxel—Anaphylactic shock—Methotrexate—hematologic cancer	5.04e-06	3.47e-05	CcSEcCtD
Docetaxel—Convulsion—Epirubicin—hematologic cancer	5.01e-06	3.45e-05	CcSEcCtD
Docetaxel—Infection—Methotrexate—hematologic cancer	5.01e-06	3.45e-05	CcSEcCtD
Docetaxel—Nausea—Etoposide—hematologic cancer	5e-06	3.44e-05	CcSEcCtD
Docetaxel—Hypertension—Epirubicin—hematologic cancer	4.99e-06	3.44e-05	CcSEcCtD
Docetaxel—Feeling abnormal—Prednisone—hematologic cancer	4.97e-06	3.42e-05	CcSEcCtD
Docetaxel—Asthenia—Dexamethasone—hematologic cancer	4.97e-06	3.42e-05	CcSEcCtD
Docetaxel—Asthenia—Betamethasone—hematologic cancer	4.97e-06	3.42e-05	CcSEcCtD
Docetaxel—Nervous system disorder—Methotrexate—hematologic cancer	4.94e-06	3.41e-05	CcSEcCtD
Docetaxel—Anaemia—Doxorubicin—hematologic cancer	4.94e-06	3.41e-05	CcSEcCtD
Docetaxel—Thrombocytopenia—Methotrexate—hematologic cancer	4.94e-06	3.4e-05	CcSEcCtD
Docetaxel—Gastrointestinal pain—Prednisone—hematologic cancer	4.93e-06	3.4e-05	CcSEcCtD
Docetaxel—Nausea—Prednisolone—hematologic cancer	4.93e-06	3.4e-05	CcSEcCtD
Docetaxel—Arthralgia—Epirubicin—hematologic cancer	4.92e-06	3.39e-05	CcSEcCtD
Docetaxel—Myalgia—Epirubicin—hematologic cancer	4.92e-06	3.39e-05	CcSEcCtD
Docetaxel—Chest pain—Epirubicin—hematologic cancer	4.92e-06	3.39e-05	CcSEcCtD
Docetaxel—Pruritus—Dexamethasone—hematologic cancer	4.9e-06	3.38e-05	CcSEcCtD
Docetaxel—Pruritus—Betamethasone—hematologic cancer	4.9e-06	3.38e-05	CcSEcCtD
Docetaxel—Skin disorder—Methotrexate—hematologic cancer	4.9e-06	3.37e-05	CcSEcCtD
Docetaxel—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	4.89e-06	3.37e-05	CcSEcCtD
Docetaxel—Vomiting—Triamcinolone—hematologic cancer	4.85e-06	3.34e-05	CcSEcCtD
Docetaxel—Rash—Triamcinolone—hematologic cancer	4.81e-06	3.32e-05	CcSEcCtD
Docetaxel—Dry mouth—Epirubicin—hematologic cancer	4.81e-06	3.32e-05	CcSEcCtD
Docetaxel—Dermatitis—Triamcinolone—hematologic cancer	4.81e-06	3.31e-05	CcSEcCtD
Docetaxel—Anorexia—Methotrexate—hematologic cancer	4.81e-06	3.31e-05	CcSEcCtD
Docetaxel—Syncope—Doxorubicin—hematologic cancer	4.8e-06	3.3e-05	CcSEcCtD
Docetaxel—Leukopenia—Doxorubicin—hematologic cancer	4.79e-06	3.3e-05	CcSEcCtD
Docetaxel—Headache—Triamcinolone—hematologic cancer	4.78e-06	3.29e-05	CcSEcCtD
Docetaxel—Body temperature increased—Prednisone—hematologic cancer	4.77e-06	3.29e-05	CcSEcCtD
Docetaxel—Abdominal pain—Prednisone—hematologic cancer	4.77e-06	3.29e-05	CcSEcCtD
Docetaxel—Confusional state—Epirubicin—hematologic cancer	4.76e-06	3.28e-05	CcSEcCtD
Docetaxel—Diarrhoea—Betamethasone—hematologic cancer	4.74e-06	3.26e-05	CcSEcCtD
Docetaxel—Diarrhoea—Dexamethasone—hematologic cancer	4.74e-06	3.26e-05	CcSEcCtD
Docetaxel—Palpitations—Doxorubicin—hematologic cancer	4.73e-06	3.26e-05	CcSEcCtD
Docetaxel—Oedema—Epirubicin—hematologic cancer	4.72e-06	3.25e-05	CcSEcCtD
Docetaxel—Anaphylactic shock—Epirubicin—hematologic cancer	4.72e-06	3.25e-05	CcSEcCtD
Docetaxel—Hypotension—Methotrexate—hematologic cancer	4.71e-06	3.25e-05	CcSEcCtD
Docetaxel—Loss of consciousness—Doxorubicin—hematologic cancer	4.7e-06	3.24e-05	CcSEcCtD
Docetaxel—Infection—Epirubicin—hematologic cancer	4.69e-06	3.23e-05	CcSEcCtD
Docetaxel—Cough—Doxorubicin—hematologic cancer	4.67e-06	3.22e-05	CcSEcCtD
Docetaxel—Shock—Epirubicin—hematologic cancer	4.64e-06	3.2e-05	CcSEcCtD
Docetaxel—Convulsion—Doxorubicin—hematologic cancer	4.63e-06	3.19e-05	CcSEcCtD
Docetaxel—Nervous system disorder—Epirubicin—hematologic cancer	4.63e-06	3.19e-05	CcSEcCtD
Docetaxel—Thrombocytopenia—Epirubicin—hematologic cancer	4.62e-06	3.18e-05	CcSEcCtD
Docetaxel—Hypertension—Doxorubicin—hematologic cancer	4.62e-06	3.18e-05	CcSEcCtD
Docetaxel—Tachycardia—Epirubicin—hematologic cancer	4.6e-06	3.17e-05	CcSEcCtD
Docetaxel—Musculoskeletal discomfort—Methotrexate—hematologic cancer	4.59e-06	3.16e-05	CcSEcCtD
Docetaxel—Skin disorder—Epirubicin—hematologic cancer	4.58e-06	3.16e-05	CcSEcCtD
Docetaxel—Dizziness—Dexamethasone—hematologic cancer	4.58e-06	3.16e-05	CcSEcCtD
Docetaxel—Dizziness—Betamethasone—hematologic cancer	4.58e-06	3.16e-05	CcSEcCtD
Docetaxel—Insomnia—Methotrexate—hematologic cancer	4.56e-06	3.14e-05	CcSEcCtD
Docetaxel—Myalgia—Doxorubicin—hematologic cancer	4.55e-06	3.14e-05	CcSEcCtD
Docetaxel—Chest pain—Doxorubicin—hematologic cancer	4.55e-06	3.14e-05	CcSEcCtD
Docetaxel—Arthralgia—Doxorubicin—hematologic cancer	4.55e-06	3.14e-05	CcSEcCtD
Docetaxel—Nausea—Triamcinolone—hematologic cancer	4.53e-06	3.12e-05	CcSEcCtD
Docetaxel—Paraesthesia—Methotrexate—hematologic cancer	4.53e-06	3.12e-05	CcSEcCtD
Docetaxel—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	4.52e-06	3.12e-05	CcSEcCtD
Docetaxel—Anorexia—Epirubicin—hematologic cancer	4.5e-06	3.1e-05	CcSEcCtD
Docetaxel—Dyspnoea—Methotrexate—hematologic cancer	4.49e-06	3.1e-05	CcSEcCtD
Docetaxel—Somnolence—Methotrexate—hematologic cancer	4.48e-06	3.09e-05	CcSEcCtD
Docetaxel—Dry mouth—Doxorubicin—hematologic cancer	4.45e-06	3.07e-05	CcSEcCtD
Docetaxel—Hypersensitivity—Prednisone—hematologic cancer	4.44e-06	3.06e-05	CcSEcCtD
Docetaxel—Dyspepsia—Methotrexate—hematologic cancer	4.44e-06	3.06e-05	CcSEcCtD
Docetaxel—Hypotension—Epirubicin—hematologic cancer	4.41e-06	3.04e-05	CcSEcCtD
Docetaxel—Vomiting—Betamethasone—hematologic cancer	4.4e-06	3.03e-05	CcSEcCtD
Docetaxel—Vomiting—Dexamethasone—hematologic cancer	4.4e-06	3.03e-05	CcSEcCtD
Docetaxel—Confusional state—Doxorubicin—hematologic cancer	4.4e-06	3.03e-05	CcSEcCtD
Docetaxel—Decreased appetite—Methotrexate—hematologic cancer	4.38e-06	3.02e-05	CcSEcCtD
Docetaxel—Rash—Dexamethasone—hematologic cancer	4.37e-06	3.01e-05	CcSEcCtD
Docetaxel—Rash—Betamethasone—hematologic cancer	4.37e-06	3.01e-05	CcSEcCtD
Docetaxel—Oedema—Doxorubicin—hematologic cancer	4.37e-06	3.01e-05	CcSEcCtD
Docetaxel—Anaphylactic shock—Doxorubicin—hematologic cancer	4.37e-06	3.01e-05	CcSEcCtD
Docetaxel—Dermatitis—Dexamethasone—hematologic cancer	4.36e-06	3.01e-05	CcSEcCtD
Docetaxel—Dermatitis—Betamethasone—hematologic cancer	4.36e-06	3.01e-05	CcSEcCtD
Docetaxel—Gastrointestinal disorder—Methotrexate—hematologic cancer	4.35e-06	3e-05	CcSEcCtD
Docetaxel—Fatigue—Methotrexate—hematologic cancer	4.35e-06	2.99e-05	CcSEcCtD
Docetaxel—Headache—Dexamethasone—hematologic cancer	4.34e-06	2.99e-05	CcSEcCtD
Docetaxel—Headache—Betamethasone—hematologic cancer	4.34e-06	2.99e-05	CcSEcCtD
Docetaxel—Infection—Doxorubicin—hematologic cancer	4.34e-06	2.99e-05	CcSEcCtD
Docetaxel—Asthenia—Prednisone—hematologic cancer	4.33e-06	2.98e-05	CcSEcCtD
Docetaxel—Pain—Methotrexate—hematologic cancer	4.31e-06	2.97e-05	CcSEcCtD
Docetaxel—Musculoskeletal discomfort—Epirubicin—hematologic cancer	4.3e-06	2.96e-05	CcSEcCtD
Docetaxel—Shock—Doxorubicin—hematologic cancer	4.29e-06	2.96e-05	CcSEcCtD
Docetaxel—Nervous system disorder—Doxorubicin—hematologic cancer	4.28e-06	2.95e-05	CcSEcCtD
Docetaxel—Thrombocytopenia—Doxorubicin—hematologic cancer	4.27e-06	2.94e-05	CcSEcCtD
Docetaxel—Pruritus—Prednisone—hematologic cancer	4.27e-06	2.94e-05	CcSEcCtD
Docetaxel—Insomnia—Epirubicin—hematologic cancer	4.27e-06	2.94e-05	CcSEcCtD
Docetaxel—Tachycardia—Doxorubicin—hematologic cancer	4.26e-06	2.94e-05	CcSEcCtD
Docetaxel—Skin disorder—Doxorubicin—hematologic cancer	4.24e-06	2.92e-05	CcSEcCtD
Docetaxel—Paraesthesia—Epirubicin—hematologic cancer	4.24e-06	2.92e-05	CcSEcCtD
Docetaxel—Dyspnoea—Epirubicin—hematologic cancer	4.21e-06	2.9e-05	CcSEcCtD
Docetaxel—Somnolence—Epirubicin—hematologic cancer	4.19e-06	2.89e-05	CcSEcCtD
Docetaxel—Anorexia—Doxorubicin—hematologic cancer	4.16e-06	2.87e-05	CcSEcCtD
Docetaxel—Feeling abnormal—Methotrexate—hematologic cancer	4.15e-06	2.86e-05	CcSEcCtD
Docetaxel—Dyspepsia—Epirubicin—hematologic cancer	4.15e-06	2.86e-05	CcSEcCtD
Docetaxel—Diarrhoea—Prednisone—hematologic cancer	4.13e-06	2.84e-05	CcSEcCtD
Docetaxel—Gastrointestinal pain—Methotrexate—hematologic cancer	4.12e-06	2.84e-05	CcSEcCtD
Docetaxel—Nausea—Betamethasone—hematologic cancer	4.11e-06	2.83e-05	CcSEcCtD
Docetaxel—Nausea—Dexamethasone—hematologic cancer	4.11e-06	2.83e-05	CcSEcCtD
Docetaxel—Decreased appetite—Epirubicin—hematologic cancer	4.1e-06	2.83e-05	CcSEcCtD
Docetaxel—Hypotension—Doxorubicin—hematologic cancer	4.08e-06	2.81e-05	CcSEcCtD
Docetaxel—Gastrointestinal disorder—Epirubicin—hematologic cancer	4.07e-06	2.81e-05	CcSEcCtD
Docetaxel—Fatigue—Epirubicin—hematologic cancer	4.07e-06	2.8e-05	CcSEcCtD
Docetaxel—Pain—Epirubicin—hematologic cancer	4.03e-06	2.78e-05	CcSEcCtD
Docetaxel—Constipation—Epirubicin—hematologic cancer	4.03e-06	2.78e-05	CcSEcCtD
Docetaxel—Dizziness—Prednisone—hematologic cancer	3.99e-06	2.75e-05	CcSEcCtD
Docetaxel—Body temperature increased—Methotrexate—hematologic cancer	3.99e-06	2.75e-05	CcSEcCtD
Docetaxel—Abdominal pain—Methotrexate—hematologic cancer	3.99e-06	2.75e-05	CcSEcCtD
Docetaxel—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	3.98e-06	2.74e-05	CcSEcCtD
Docetaxel—Insomnia—Doxorubicin—hematologic cancer	3.95e-06	2.72e-05	CcSEcCtD
Docetaxel—Paraesthesia—Doxorubicin—hematologic cancer	3.92e-06	2.7e-05	CcSEcCtD
Docetaxel—Dyspnoea—Doxorubicin—hematologic cancer	3.89e-06	2.68e-05	CcSEcCtD
Docetaxel—Feeling abnormal—Epirubicin—hematologic cancer	3.89e-06	2.68e-05	CcSEcCtD
Docetaxel—Somnolence—Doxorubicin—hematologic cancer	3.88e-06	2.67e-05	CcSEcCtD
Docetaxel—Gastrointestinal pain—Epirubicin—hematologic cancer	3.86e-06	2.66e-05	CcSEcCtD
Docetaxel—Dyspepsia—Doxorubicin—hematologic cancer	3.84e-06	2.65e-05	CcSEcCtD
Docetaxel—Vomiting—Prednisone—hematologic cancer	3.84e-06	2.64e-05	CcSEcCtD
Docetaxel—Rash—Prednisone—hematologic cancer	3.8e-06	2.62e-05	CcSEcCtD
Docetaxel—Dermatitis—Prednisone—hematologic cancer	3.8e-06	2.62e-05	CcSEcCtD
Docetaxel—Decreased appetite—Doxorubicin—hematologic cancer	3.79e-06	2.61e-05	CcSEcCtD
Docetaxel—Headache—Prednisone—hematologic cancer	3.78e-06	2.6e-05	CcSEcCtD
Docetaxel—Gastrointestinal disorder—Doxorubicin—hematologic cancer	3.77e-06	2.6e-05	CcSEcCtD
Docetaxel—Fatigue—Doxorubicin—hematologic cancer	3.76e-06	2.59e-05	CcSEcCtD
Docetaxel—Pain—Doxorubicin—hematologic cancer	3.73e-06	2.57e-05	CcSEcCtD
Docetaxel—Constipation—Doxorubicin—hematologic cancer	3.73e-06	2.57e-05	CcSEcCtD
Docetaxel—Abdominal pain—Epirubicin—hematologic cancer	3.73e-06	2.57e-05	CcSEcCtD
Docetaxel—Body temperature increased—Epirubicin—hematologic cancer	3.73e-06	2.57e-05	CcSEcCtD
Docetaxel—Hypersensitivity—Methotrexate—hematologic cancer	3.71e-06	2.56e-05	CcSEcCtD
Docetaxel—Asthenia—Methotrexate—hematologic cancer	3.62e-06	2.49e-05	CcSEcCtD
Docetaxel—Feeling abnormal—Doxorubicin—hematologic cancer	3.6e-06	2.48e-05	CcSEcCtD
Docetaxel—Nausea—Prednisone—hematologic cancer	3.58e-06	2.47e-05	CcSEcCtD
Docetaxel—Gastrointestinal pain—Doxorubicin—hematologic cancer	3.57e-06	2.46e-05	CcSEcCtD
Docetaxel—Pruritus—Methotrexate—hematologic cancer	3.57e-06	2.46e-05	CcSEcCtD
Docetaxel—Hypersensitivity—Epirubicin—hematologic cancer	3.48e-06	2.39e-05	CcSEcCtD
Docetaxel—Abdominal pain—Doxorubicin—hematologic cancer	3.45e-06	2.38e-05	CcSEcCtD
Docetaxel—Body temperature increased—Doxorubicin—hematologic cancer	3.45e-06	2.38e-05	CcSEcCtD
Docetaxel—Diarrhoea—Methotrexate—hematologic cancer	3.45e-06	2.38e-05	CcSEcCtD
Docetaxel—Asthenia—Epirubicin—hematologic cancer	3.38e-06	2.33e-05	CcSEcCtD
Docetaxel—Pruritus—Epirubicin—hematologic cancer	3.34e-06	2.3e-05	CcSEcCtD
Docetaxel—Dizziness—Methotrexate—hematologic cancer	3.33e-06	2.3e-05	CcSEcCtD
Docetaxel—Diarrhoea—Epirubicin—hematologic cancer	3.23e-06	2.22e-05	CcSEcCtD
Docetaxel—Hypersensitivity—Doxorubicin—hematologic cancer	3.22e-06	2.22e-05	CcSEcCtD
Docetaxel—Vomiting—Methotrexate—hematologic cancer	3.21e-06	2.21e-05	CcSEcCtD
Docetaxel—Rash—Methotrexate—hematologic cancer	3.18e-06	2.19e-05	CcSEcCtD
Docetaxel—Dermatitis—Methotrexate—hematologic cancer	3.18e-06	2.19e-05	CcSEcCtD
Docetaxel—Headache—Methotrexate—hematologic cancer	3.16e-06	2.18e-05	CcSEcCtD
Docetaxel—Asthenia—Doxorubicin—hematologic cancer	3.13e-06	2.16e-05	CcSEcCtD
Docetaxel—Dizziness—Epirubicin—hematologic cancer	3.12e-06	2.15e-05	CcSEcCtD
Docetaxel—Pruritus—Doxorubicin—hematologic cancer	3.09e-06	2.13e-05	CcSEcCtD
Docetaxel—Vomiting—Epirubicin—hematologic cancer	3e-06	2.07e-05	CcSEcCtD
Docetaxel—Nausea—Methotrexate—hematologic cancer	2.99e-06	2.06e-05	CcSEcCtD
Docetaxel—Diarrhoea—Doxorubicin—hematologic cancer	2.99e-06	2.06e-05	CcSEcCtD
Docetaxel—Rash—Epirubicin—hematologic cancer	2.97e-06	2.05e-05	CcSEcCtD
Docetaxel—Dermatitis—Epirubicin—hematologic cancer	2.97e-06	2.05e-05	CcSEcCtD
Docetaxel—Headache—Epirubicin—hematologic cancer	2.96e-06	2.04e-05	CcSEcCtD
Docetaxel—Dizziness—Doxorubicin—hematologic cancer	2.89e-06	1.99e-05	CcSEcCtD
Docetaxel—Nausea—Epirubicin—hematologic cancer	2.8e-06	1.93e-05	CcSEcCtD
Docetaxel—Vomiting—Doxorubicin—hematologic cancer	2.78e-06	1.91e-05	CcSEcCtD
Docetaxel—Rash—Doxorubicin—hematologic cancer	2.75e-06	1.9e-05	CcSEcCtD
Docetaxel—Dermatitis—Doxorubicin—hematologic cancer	2.75e-06	1.89e-05	CcSEcCtD
Docetaxel—Headache—Doxorubicin—hematologic cancer	2.73e-06	1.88e-05	CcSEcCtD
Docetaxel—Nausea—Doxorubicin—hematologic cancer	2.59e-06	1.79e-05	CcSEcCtD
Docetaxel—EGFR—Immune System—MDM2—hematologic cancer	7.65e-07	8.28e-06	CbGpPWpGaD
Docetaxel—EGFR—Disease—FGF2—hematologic cancer	7.55e-07	8.17e-06	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—IL2RA—hematologic cancer	7.54e-07	8.16e-06	CbGpPWpGaD
Docetaxel—ABCB1—Transmembrane transport of small molecules—CREBBP—hematologic cancer	7.51e-07	8.12e-06	CbGpPWpGaD
Docetaxel—ABCC1—Disease—MDM2—hematologic cancer	7.5e-07	8.11e-06	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—IDH2—hematologic cancer	7.49e-07	8.1e-06	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—HMMR—hematologic cancer	7.49e-07	8.1e-06	CbGpPWpGaD
Docetaxel—EGFR—Signaling by GPCR—IL2—hematologic cancer	7.48e-07	8.1e-06	CbGpPWpGaD
Docetaxel—EGFR—Adaptive Immune System—PIK3CA—hematologic cancer	7.48e-07	8.09e-06	CbGpPWpGaD
Docetaxel—SLCO1B3—Metabolism—PTEN—hematologic cancer	7.47e-07	8.08e-06	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—TERT—hematologic cancer	7.46e-07	8.07e-06	CbGpPWpGaD
Docetaxel—EGFR—Disease—PIK3R1—hematologic cancer	7.45e-07	8.06e-06	CbGpPWpGaD
Docetaxel—EGFR—Immune System—PIK3CB—hematologic cancer	7.45e-07	8.05e-06	CbGpPWpGaD
Docetaxel—EGFR—Immune System—MTOR—hematologic cancer	7.45e-07	8.05e-06	CbGpPWpGaD
Docetaxel—EGFR—Immune System—CD4—hematologic cancer	7.43e-07	8.04e-06	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism—CREBBP—hematologic cancer	7.39e-07	7.99e-06	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—GSTP1—hematologic cancer	7.37e-07	7.97e-06	CbGpPWpGaD
Docetaxel—ABCC1—Disease—PIK3CB—hematologic cancer	7.29e-07	7.89e-06	CbGpPWpGaD
Docetaxel—ABCC1—Disease—MTOR—hematologic cancer	7.29e-07	7.89e-06	CbGpPWpGaD
Docetaxel—ABCC1—Disease—CD4—hematologic cancer	7.28e-07	7.87e-06	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—PDGFB—hematologic cancer	7.28e-07	7.87e-06	CbGpPWpGaD
Docetaxel—EGFR—Disease—JAK2—hematologic cancer	7.24e-07	7.83e-06	CbGpPWpGaD
Docetaxel—EGFR—Innate Immune System—HRAS—hematologic cancer	7.21e-07	7.8e-06	CbGpPWpGaD
Docetaxel—EGFR—Developmental Biology—AKT1—hematologic cancer	7.21e-07	7.8e-06	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism—CREBBP—hematologic cancer	7.15e-07	7.73e-06	CbGpPWpGaD
Docetaxel—SLCO1B3—Metabolism—EP300—hematologic cancer	7.12e-07	7.7e-06	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—TSC2—hematologic cancer	7.11e-07	7.69e-06	CbGpPWpGaD
Docetaxel—BCL2—Immune System—HRAS—hematologic cancer	7.1e-07	7.68e-06	CbGpPWpGaD
Docetaxel—EGFR—Disease—MDM2—hematologic cancer	7.07e-07	7.64e-06	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—ARNTL—hematologic cancer	7.05e-07	7.62e-06	CbGpPWpGaD
Docetaxel—ABCB1—Transmembrane transport of small molecules—ALB—hematologic cancer	7.03e-07	7.6e-06	CbGpPWpGaD
Docetaxel—ABCG2—Metabolism—PIK3CG—hematologic cancer	7.02e-07	7.59e-06	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism—PIK3CD—hematologic cancer	7.01e-07	7.58e-06	CbGpPWpGaD
Docetaxel—EGFR—Immune System—CDKN1B—hematologic cancer	6.99e-07	7.56e-06	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—ABCB1—hematologic cancer	6.97e-07	7.54e-06	CbGpPWpGaD
Docetaxel—CYP3A7—Metabolism—PIK3CG—hematologic cancer	6.95e-07	7.52e-06	CbGpPWpGaD
Docetaxel—EGFR—Adaptive Immune System—HRAS—hematologic cancer	6.92e-07	7.49e-06	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism—ALB—hematologic cancer	6.92e-07	7.48e-06	CbGpPWpGaD
Docetaxel—EGFR—Innate Immune System—IL6—hematologic cancer	6.9e-07	7.46e-06	CbGpPWpGaD
Docetaxel—EGFR—Disease—MTOR—hematologic cancer	6.88e-07	7.44e-06	CbGpPWpGaD
Docetaxel—EGFR—Disease—PIK3CB—hematologic cancer	6.88e-07	7.44e-06	CbGpPWpGaD
Docetaxel—EGFR—Immune System—IL1B—hematologic cancer	6.86e-07	7.42e-06	CbGpPWpGaD
Docetaxel—EGFR—Disease—CD4—hematologic cancer	6.86e-07	7.42e-06	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—ACP5—hematologic cancer	6.85e-07	7.41e-06	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—CA9—hematologic cancer	6.85e-07	7.41e-06	CbGpPWpGaD
Docetaxel—ABCC1—Disease—CDKN1B—hematologic cancer	6.85e-07	7.4e-06	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—FGFR3—hematologic cancer	6.84e-07	7.4e-06	CbGpPWpGaD
Docetaxel—EGFR—Immune System—IL2—hematologic cancer	6.84e-07	7.4e-06	CbGpPWpGaD
Docetaxel—BCL2—Immune System—IL6—hematologic cancer	6.8e-07	7.35e-06	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism—PIK3CD—hematologic cancer	6.78e-07	7.33e-06	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—MAPK14—hematologic cancer	6.78e-07	7.33e-06	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—NCOR1—hematologic cancer	6.77e-07	7.32e-06	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—GSTM1—hematologic cancer	6.77e-07	7.32e-06	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—NCOR2—hematologic cancer	6.76e-07	7.32e-06	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism—ALB—hematologic cancer	6.69e-07	7.24e-06	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—CD44—hematologic cancer	6.66e-07	7.21e-06	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—NQO1—hematologic cancer	6.66e-07	7.21e-06	CbGpPWpGaD
Docetaxel—EGFR—Immune System—JUN—hematologic cancer	6.65e-07	7.2e-06	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—ESR1—hematologic cancer	6.65e-07	7.19e-06	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism—PIK3R1—hematologic cancer	6.62e-07	7.16e-06	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—FN1—hematologic cancer	6.57e-07	7.1e-06	CbGpPWpGaD
Docetaxel—ABCG2—Metabolism—CREBBP—hematologic cancer	6.5e-07	7.03e-06	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—BAD—hematologic cancer	6.49e-07	7.02e-06	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—NFKBIA—hematologic cancer	6.49e-07	7.02e-06	CbGpPWpGaD
Docetaxel—EGFR—Disease—CDKN1B—hematologic cancer	6.45e-07	6.98e-06	CbGpPWpGaD
Docetaxel—EGFR—Immune System—CDKN1A—hematologic cancer	6.45e-07	6.98e-06	CbGpPWpGaD
Docetaxel—CYP3A7—Metabolism—CREBBP—hematologic cancer	6.45e-07	6.97e-06	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—IDH1—hematologic cancer	6.44e-07	6.97e-06	CbGpPWpGaD
Docetaxel—EGFR—Immune System—PTEN—hematologic cancer	6.43e-07	6.96e-06	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—NOTCH1—hematologic cancer	6.43e-07	6.95e-06	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism—PIK3R1—hematologic cancer	6.4e-07	6.92e-06	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—GSTO1—hematologic cancer	6.37e-07	6.89e-06	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—TXN—hematologic cancer	6.37e-07	6.89e-06	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—ABCC3—hematologic cancer	6.37e-07	6.89e-06	CbGpPWpGaD
Docetaxel—EGFR—Innate Immune System—AKT1—hematologic cancer	6.37e-07	6.89e-06	CbGpPWpGaD
Docetaxel—ABCC1—Disease—CDKN1A—hematologic cancer	6.32e-07	6.83e-06	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—CYCS—hematologic cancer	6.31e-07	6.82e-06	CbGpPWpGaD
Docetaxel—ABCC1—Disease—PTEN—hematologic cancer	6.3e-07	6.82e-06	CbGpPWpGaD
Docetaxel—EGFR—Immune System—MAPK8—hematologic cancer	6.29e-07	6.81e-06	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—CD80—hematologic cancer	6.29e-07	6.81e-06	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—PIK3CG—hematologic cancer	6.28e-07	6.8e-06	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—KIT—hematologic cancer	6.28e-07	6.8e-06	CbGpPWpGaD
Docetaxel—EGFR—Signaling by GPCR—NRAS—hematologic cancer	6.28e-07	6.8e-06	CbGpPWpGaD
Docetaxel—BCL2—Immune System—AKT1—hematologic cancer	6.27e-07	6.78e-06	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—HSP90AA1—hematologic cancer	6.27e-07	6.78e-06	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—SPHK1—hematologic cancer	6.24e-07	6.74e-06	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—PTPN11—hematologic cancer	6.17e-07	6.68e-06	CbGpPWpGaD
Docetaxel—ABCG2—Metabolism—PIK3CD—hematologic cancer	6.17e-07	6.67e-06	CbGpPWpGaD
Docetaxel—EGFR—Immune System—EP300—hematologic cancer	6.14e-07	6.64e-06	CbGpPWpGaD
Docetaxel—EGFR—Adaptive Immune System—AKT1—hematologic cancer	6.11e-07	6.61e-06	CbGpPWpGaD
Docetaxel—CYP3A7—Metabolism—PIK3CD—hematologic cancer	6.11e-07	6.61e-06	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism—PIK3CB—hematologic cancer	6.11e-07	6.61e-06	CbGpPWpGaD
Docetaxel—ABCG2—Metabolism—ALB—hematologic cancer	6.09e-07	6.58e-06	CbGpPWpGaD
Docetaxel—CYP3A7—Metabolism—ALB—hematologic cancer	6.03e-07	6.53e-06	CbGpPWpGaD
Docetaxel—EGFR—Signaling by GPCR—MAPK3—hematologic cancer	6.02e-07	6.51e-06	CbGpPWpGaD
Docetaxel—ABCC1—Disease—EP300—hematologic cancer	6.01e-07	6.5e-06	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—UGT1A1—hematologic cancer	5.99e-07	6.48e-06	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—MTHFR—hematologic cancer	5.98e-07	6.47e-06	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—CREB1—hematologic cancer	5.98e-07	6.47e-06	CbGpPWpGaD
Docetaxel—EGFR—Immune System—SRC—hematologic cancer	5.97e-07	6.45e-06	CbGpPWpGaD
Docetaxel—EGFR—Disease—CDKN1A—hematologic cancer	5.95e-07	6.44e-06	CbGpPWpGaD
Docetaxel—EGFR—Disease—PTEN—hematologic cancer	5.94e-07	6.43e-06	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism—PIK3CB—hematologic cancer	5.91e-07	6.39e-06	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—BRAF—hematologic cancer	5.91e-07	6.39e-06	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—CCL2—hematologic cancer	5.85e-07	6.33e-06	CbGpPWpGaD
Docetaxel—ABCC1—Disease—SRC—hematologic cancer	5.85e-07	6.32e-06	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—IL6R—hematologic cancer	5.83e-07	6.31e-06	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—SLC22A1—hematologic cancer	5.83e-07	6.3e-06	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—CRABP1—hematologic cancer	5.83e-07	6.3e-06	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—CREBBP—hematologic cancer	5.83e-07	6.3e-06	CbGpPWpGaD
Docetaxel—ABCG2—Metabolism—PIK3R1—hematologic cancer	5.82e-07	6.3e-06	CbGpPWpGaD
Docetaxel—CYP3A7—Metabolism—PIK3R1—hematologic cancer	5.77e-07	6.24e-06	CbGpPWpGaD
Docetaxel—EGFR—Immune System—STAT3—hematologic cancer	5.75e-07	6.22e-06	CbGpPWpGaD
Docetaxel—EGFR—Immune System—NRAS—hematologic cancer	5.74e-07	6.21e-06	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—ALOX5—hematologic cancer	5.68e-07	6.14e-06	CbGpPWpGaD
Docetaxel—EGFR—Disease—EP300—hematologic cancer	5.67e-07	6.13e-06	CbGpPWpGaD
Docetaxel—ABCC1—Disease—STAT3—hematologic cancer	5.64e-07	6.1e-06	CbGpPWpGaD
Docetaxel—ABCC1—Disease—NRAS—hematologic cancer	5.62e-07	6.08e-06	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—MAP2K1—hematologic cancer	5.56e-07	6.01e-06	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—GSTP1—hematologic cancer	5.56e-07	6.01e-06	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—PIK3CD—hematologic cancer	5.52e-07	5.97e-06	CbGpPWpGaD
Docetaxel—EGFR—Disease—SRC—hematologic cancer	5.51e-07	5.96e-06	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—NUP98—hematologic cancer	5.5e-07	5.95e-06	CbGpPWpGaD
Docetaxel—EGFR—Immune System—MAPK3—hematologic cancer	5.5e-07	5.95e-06	CbGpPWpGaD
Docetaxel—EGFR—Signaling by GPCR—KRAS—hematologic cancer	5.41e-07	5.85e-06	CbGpPWpGaD
Docetaxel—ABCC1—Disease—MAPK3—hematologic cancer	5.39e-07	5.82e-06	CbGpPWpGaD
Docetaxel—ABCG2—Metabolism—PIK3CB—hematologic cancer	5.38e-07	5.81e-06	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—NCOA3—hematologic cancer	5.34e-07	5.77e-06	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—ADCY7—hematologic cancer	5.34e-07	5.77e-06	CbGpPWpGaD
Docetaxel—CYP3A7—Metabolism—PIK3CB—hematologic cancer	5.33e-07	5.76e-06	CbGpPWpGaD
Docetaxel—EGFR—Disease—STAT3—hematologic cancer	5.31e-07	5.75e-06	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—NUP214—hematologic cancer	5.3e-07	5.73e-06	CbGpPWpGaD
Docetaxel—EGFR—Disease—NRAS—hematologic cancer	5.3e-07	5.73e-06	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—FGF2—hematologic cancer	5.29e-07	5.72e-06	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism—PTEN—hematologic cancer	5.28e-07	5.71e-06	CbGpPWpGaD
Docetaxel—SLCO1B3—Metabolism—PIK3CA—hematologic cancer	5.27e-07	5.7e-06	CbGpPWpGaD
Docetaxel—ABCC1—Disease—MYC—hematologic cancer	5.24e-07	5.67e-06	CbGpPWpGaD
Docetaxel—ABCC1—Disease—TGFB1—hematologic cancer	5.23e-07	5.65e-06	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—PIK3R1—hematologic cancer	5.22e-07	5.64e-06	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—MTR—hematologic cancer	5.19e-07	5.62e-06	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—ABCG2—hematologic cancer	5.19e-07	5.62e-06	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—NCOR1—hematologic cancer	5.11e-07	5.52e-06	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—GSTM1—hematologic cancer	5.11e-07	5.52e-06	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism—PTEN—hematologic cancer	5.11e-07	5.52e-06	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—ENO2—hematologic cancer	5.09e-07	5.51e-06	CbGpPWpGaD
Docetaxel—EGFR—Disease—MAPK3—hematologic cancer	5.08e-07	5.49e-06	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—JAK2—hematologic cancer	5.07e-07	5.48e-06	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism—EP300—hematologic cancer	5.03e-07	5.44e-06	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—PIK3CG—hematologic cancer	5.03e-07	5.44e-06	CbGpPWpGaD
Docetaxel—EGFR—Signaling by GPCR—PIK3CA—hematologic cancer	4.97e-07	5.37e-06	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—MDM2—hematologic cancer	4.95e-07	5.35e-06	CbGpPWpGaD
Docetaxel—EGFR—Immune System—KRAS—hematologic cancer	4.94e-07	5.34e-06	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—GSTT1—hematologic cancer	4.94e-07	5.34e-06	CbGpPWpGaD
Docetaxel—EGFR—Disease—MYC—hematologic cancer	4.94e-07	5.34e-06	CbGpPWpGaD
Docetaxel—EGFR—Disease—TGFB1—hematologic cancer	4.93e-07	5.33e-06	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism—EP300—hematologic cancer	4.87e-07	5.27e-06	CbGpPWpGaD
Docetaxel—ABCC1—Disease—KRAS—hematologic cancer	4.84e-07	5.23e-06	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—SDC1—hematologic cancer	4.83e-07	5.22e-06	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—MTOR—hematologic cancer	4.81e-07	5.21e-06	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—PIK3CB—hematologic cancer	4.81e-07	5.21e-06	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—CREBBP—hematologic cancer	4.66e-07	5.04e-06	CbGpPWpGaD
Docetaxel—ABCG2—Metabolism—PTEN—hematologic cancer	4.64e-07	5.02e-06	CbGpPWpGaD
Docetaxel—CYP3A7—Metabolism—PTEN—hematologic cancer	4.6e-07	4.98e-06	CbGpPWpGaD
Docetaxel—EGFR—Signaling by GPCR—HRAS—hematologic cancer	4.6e-07	4.97e-06	CbGpPWpGaD
Docetaxel—EGFR—Disease—KRAS—hematologic cancer	4.56e-07	4.93e-06	CbGpPWpGaD
Docetaxel—EGFR—Immune System—PIK3CA—hematologic cancer	4.54e-07	4.91e-06	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—CDKN1B—hematologic cancer	4.52e-07	4.89e-06	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—MTHFR—hematologic cancer	4.51e-07	4.88e-06	CbGpPWpGaD
Docetaxel—ABCC1—Disease—PIK3CA—hematologic cancer	4.45e-07	4.81e-06	CbGpPWpGaD
Docetaxel—ABCG2—Metabolism—EP300—hematologic cancer	4.43e-07	4.79e-06	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—CASP3—hematologic cancer	4.43e-07	4.79e-06	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—IL2—hematologic cancer	4.42e-07	4.78e-06	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—PIK3CD—hematologic cancer	4.42e-07	4.78e-06	CbGpPWpGaD
Docetaxel—EGFR—Signaling by GPCR—IL6—hematologic cancer	4.4e-07	4.76e-06	CbGpPWpGaD
Docetaxel—CYP3A7—Metabolism—EP300—hematologic cancer	4.39e-07	4.75e-06	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—ALB—hematologic cancer	4.36e-07	4.72e-06	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—CCND1—hematologic cancer	4.31e-07	4.66e-06	CbGpPWpGaD
Docetaxel—SLCO1B3—Metabolism—AKT1—hematologic cancer	4.3e-07	4.65e-06	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—JUN—hematologic cancer	4.3e-07	4.65e-06	CbGpPWpGaD
Docetaxel—EGFR—Immune System—HRAS—hematologic cancer	4.2e-07	4.54e-06	CbGpPWpGaD
Docetaxel—EGFR—Disease—PIK3CA—hematologic cancer	4.19e-07	4.53e-06	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—PIK3R1—hematologic cancer	4.17e-07	4.51e-06	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—CDKN1A—hematologic cancer	4.17e-07	4.51e-06	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—PTEN—hematologic cancer	4.16e-07	4.5e-06	CbGpPWpGaD
Docetaxel—ABCC1—Disease—HRAS—hematologic cancer	4.11e-07	4.45e-06	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—CD44—hematologic cancer	4.11e-07	4.44e-06	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—NQO1—hematologic cancer	4.11e-07	4.44e-06	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—MAPK8—hematologic cancer	4.07e-07	4.4e-06	CbGpPWpGaD
Docetaxel—EGFR—Signaling by GPCR—AKT1—hematologic cancer	4.06e-07	4.39e-06	CbGpPWpGaD
Docetaxel—EGFR—Immune System—IL6—hematologic cancer	4.02e-07	4.35e-06	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—EP300—hematologic cancer	3.97e-07	4.29e-06	CbGpPWpGaD
Docetaxel—ABCC1—Disease—IL6—hematologic cancer	3.94e-07	4.26e-06	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—CYCS—hematologic cancer	3.89e-07	4.2e-06	CbGpPWpGaD
Docetaxel—EGFR—Disease—HRAS—hematologic cancer	3.88e-07	4.19e-06	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	3.86e-07	4.18e-06	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—SRC—hematologic cancer	3.86e-07	4.17e-06	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—PIK3CB—hematologic cancer	3.85e-07	4.17e-06	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—PIK3CG—hematologic cancer	3.79e-07	4.1e-06	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—VEGFA—hematologic cancer	3.76e-07	4.06e-06	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism—PIK3CA—hematologic cancer	3.72e-07	4.03e-06	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—STAT3—hematologic cancer	3.72e-07	4.02e-06	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—NRAS—hematologic cancer	3.71e-07	4.01e-06	CbGpPWpGaD
Docetaxel—EGFR—Disease—IL6—hematologic cancer	3.71e-07	4.01e-06	CbGpPWpGaD
Docetaxel—EGFR—Immune System—AKT1—hematologic cancer	3.71e-07	4.01e-06	CbGpPWpGaD
Docetaxel—ABCC1—Disease—AKT1—hematologic cancer	3.63e-07	3.93e-06	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism—PIK3CA—hematologic cancer	3.6e-07	3.9e-06	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—MAPK3—hematologic cancer	3.55e-07	3.84e-06	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—CREBBP—hematologic cancer	3.52e-07	3.8e-06	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—MYC—hematologic cancer	3.46e-07	3.74e-06	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—TGFB1—hematologic cancer	3.45e-07	3.73e-06	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—GSTP1—hematologic cancer	3.42e-07	3.7e-06	CbGpPWpGaD
Docetaxel—EGFR—Disease—AKT1—hematologic cancer	3.42e-07	3.7e-06	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—PIK3CD—hematologic cancer	3.33e-07	3.61e-06	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—PTEN—hematologic cancer	3.33e-07	3.6e-06	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—ALB—hematologic cancer	3.29e-07	3.56e-06	CbGpPWpGaD
Docetaxel—ABCG2—Metabolism—PIK3CA—hematologic cancer	3.28e-07	3.54e-06	CbGpPWpGaD
Docetaxel—CYP3A7—Metabolism—PIK3CA—hematologic cancer	3.25e-07	3.51e-06	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—ABCB1—hematologic cancer	3.24e-07	3.51e-06	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—KRAS—hematologic cancer	3.19e-07	3.46e-06	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—EP300—hematologic cancer	3.17e-07	3.43e-06	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—PIK3R1—hematologic cancer	3.15e-07	3.41e-06	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—NCOR1—hematologic cancer	3.15e-07	3.4e-06	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—GSTM1—hematologic cancer	3.15e-07	3.4e-06	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism—AKT1—hematologic cancer	3.04e-07	3.29e-06	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism—AKT1—hematologic cancer	2.94e-07	3.18e-06	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—PIK3CA—hematologic cancer	2.93e-07	3.17e-06	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—PIK3CB—hematologic cancer	2.91e-07	3.14e-06	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—TP53—hematologic cancer	2.84e-07	3.07e-06	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—MTHFR—hematologic cancer	2.78e-07	3.01e-06	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—HRAS—hematologic cancer	2.72e-07	2.94e-06	CbGpPWpGaD
Docetaxel—ABCG2—Metabolism—AKT1—hematologic cancer	2.68e-07	2.9e-06	CbGpPWpGaD
Docetaxel—CYP3A7—Metabolism—AKT1—hematologic cancer	2.65e-07	2.87e-06	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—IL6—hematologic cancer	2.6e-07	2.81e-06	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—PTEN—hematologic cancer	2.51e-07	2.72e-06	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—AKT1—hematologic cancer	2.4e-07	2.59e-06	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—EP300—hematologic cancer	2.39e-07	2.59e-06	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—PIK3CA—hematologic cancer	2.35e-07	2.54e-06	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—PIK3CG—hematologic cancer	2.34e-07	2.53e-06	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—CREBBP—hematologic cancer	2.17e-07	2.34e-06	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—PIK3CD—hematologic cancer	2.05e-07	2.22e-06	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—ALB—hematologic cancer	2.03e-07	2.19e-06	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—PIK3R1—hematologic cancer	1.94e-07	2.1e-06	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—AKT1—hematologic cancer	1.92e-07	2.07e-06	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—PIK3CB—hematologic cancer	1.79e-07	1.94e-06	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—PIK3CA—hematologic cancer	1.77e-07	1.92e-06	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—PTEN—hematologic cancer	1.55e-07	1.67e-06	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—EP300—hematologic cancer	1.48e-07	1.6e-06	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—AKT1—hematologic cancer	1.45e-07	1.57e-06	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—PIK3CA—hematologic cancer	1.09e-07	1.18e-06	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—AKT1—hematologic cancer	8.92e-08	9.64e-07	CbGpPWpGaD
